Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Breyer, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Breyer, J. A.

Journal of the American Society of Nephrology, Vol 6, 1523-1529, Copyright © 1995 by American Society of Nephrology

REVIEWS

Medical management of nephropathy in type I diabetes mellitus: current recommendations

JA Breyer
Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN 37232-2372, USA.

Diabetic nephropathy is the single most common cause of end-stage renal disease in the United States. Recently, several major therapeutic interventions have been developed and demonstrated to slow or halt the progression of renal failure in patients with diabetes and diabetic kidney disease. The Diabetes Control and Complications Trial demonstrated that microalbuminuria developed in fewer patients in the intensive blood sugar control group than in the conventional therapy group. Similarly, the risk of developing proteinuria was reduced by intensive blood sugar control. Multiple studies have demonstrated that in patients with insulin-dependent diabetes and proteinuria, lowering the systemic blood pressure slows the rate of decline in renal function and improves patients' survival. In the recently completed trial of ACE inhibition in diabetic nephropathy, ACE inhibitors were specifically shown to decrease dramatically the risk of doubling of serum creatinine or reaching a combined outcome of end-stage renal disease or death. In studies in small numbers of patients with insulin-dependent diabetes and established diabetic nephropathy, dietary protein restriction has also been demonstrated to slow the rate of decline of renal function. New potential interventions currently undergoing study include the use of aldose reductase inhibitors, the use of drugs that prevent the formation of advanced glycosylation end-products, and the use of angiotensin II receptor antagonists. Thus, several established benefits have recently been demonstrated to help prevent the development of or slow the progression of diabetic nephropathy, including blood pressure control, blood sugar control, and treatment with ACE inhibitors. Dietary protein restriction may also be of benefit. Multiple new interventions are undergoing clinical trials currently.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
L. R. James, A. Ingram, H. Ly, K. Thai, L. Cai, and J. W. Scholey
Angiotensin II activates the GFAT promoter in mesangial cells
Am J Physiol Renal Physiol, July 1, 2001; 281(1): F151 - F162.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Remuzzi and T. Bertani
Pathophysiology of Progressive Nephropathies
N. Engl. J. Med., November 12, 1998; 339(20): 1448 - 1456.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
S. S. El-Dahr, S. Dipp, and W. H. Baricos
Bradykinin stimulates the ERKright-arrowElk-1right-arrowFos/AP-1 pathway in mesangial cells
Am J Physiol Renal Physiol, September 1, 1998; 275(3): F343 - F352.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673